Other substances

Brequinar

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
3
 Clinical trials

 

Supporting references

Link Tested on Impact factor Notes Publication date
Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19
Preprint Screening 		VERO E6 cell cultures Jul/13/2020

AI-suggested references

Link Publication date
Artificial intelligence approach fighting COVID-19 with repurposing drugs
May/15/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT05166876 Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19 Recruiting Phase 2 Feb/01/2022 Jul/01/2022
  • Alternative id - CCB-CRISIS-04
  • Interventions - Drug: Brequinar Sodium|Drug: Dipyridamole 75 MG|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - RIMS - Government Medical College, Srikakulam, Andhra Pradesh, India|King George Hospital, Visakhapatnam, Andhra Pradesh, India|JIPMER Hospital, Pondicherry, Puducherry, India|Noble Hospital, Hadapsar, Pune, India|Panimalar Hospital, Chennai, Tamil Nadu, India
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 112
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Safety and tolerability of the brequinar-dipyridamole combination in COVID-19 subjects|Reduction of SARS-CoV-2 levels using qPCR through Day 29 and at days 4, 8, 12, 15, 22, and 29|Reduction in time to symptom improvement|Reduction in percentage of subjects requiring hospital admission/re-admission as an in-patient for >24 hours|Reduction in percentage of subjects requiring medical attended visits, e.g., hospitalization, emergency room visits, Urgent Care/Family Doctor visits|Reduction in percentage of subjects requiring supplemental support such as oxygen
NCT04575038 CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 Completed Phase 2 Nov/19/2020 Apr/28/2021
  • Alternative id - CCB-CRISIS-02
  • Interventions - Drug: Brequinar|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Central Alabama Research, Homewood, Alabama, United States|Ark Clinical Research, Long Beach, California, United States|Doral Medical Research, Doral, Florida, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Monroe Biomedical Research, Monroe, North Carolina, United States|Wilmington Health, Wilmington, North Carolina, United States|Remington-Davis, Inc., Columbus, Ohio, United States|Toledo Institute of Clinical Research, Toledo, Ohio, United States|VitaLink - Gaffney, Gaffney, South Carolina, United States|Self Regional Healthcare Research Center - Self Medical Group, Greenwood, South Carolina, United States|VitaLink Research, Spartanburg, South Carolina, United States|Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States|Centex Studies, Inc. - McAllen, McAllen, Texas, United States|Synexus Clinical Research US, Inc. - Olympus Family Medicine, Salt Lake City, Utah, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 115
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - SARS-CoV-2 viral load|Rates of AEs and SAEs including laboratory assessments|Viral shedding duration|Hospital Admission
NCT04425252 Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19 Completed Phase 1|Phase 2 Aug/19/2020 Jan/12/2021
  • Alternative id - CCB-CRISIS-01
  • Interventions - Drug: Brequinar|Other: Standard of Care
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Hartford Hospital, Hartford, Connecticut, United States|Baptist Medical Center, Jacksonville, Florida, United States|University of South Florida/Tampa General, Tampa, Florida, United States|University of New Mexico, Albuquerque, New Mexico, United States|Temple University, Philadelphia, Pennsylvania, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 25
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Safety/Tolerability Assessed by Rates of Grade 3 or 4 Post Randomization Adverse Events|Safety/Tolerability as Assessed by Rates of Serious Adverse Events (SAEs).|Safety/Tolerability Measured by Mortality at Day 29|Hospitalization Status|Duration of Hospitalization|NEWS2 Score
Export (.csv)